MarketCapExport financials
G1 Therapeutics (GTHX)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
G1 Therapeutics Balance Sheet 2023-2011 | GTHX
Brief overview of G1 Therapeutics's assets and capital
The balance sheet is assessed across five available annual reports spanning 2019 to 2023.
Assets declined from $284.8 million to $121.5 million, or -57.3%. The contraction calls for context such as disposals, restructuring or weaker operations.
Liabilities grew faster than assets: +194% versus -57.3%. A substantial part of expansion was externally funded.
Equity finances 29.1% of the balance sheet, compared with 89.7% at the start. The cushion remains adequate.
Each unit of equity supports about 0.54x of net debt. Dependence on debt remains comfortable.
Cash equals 26.5% of the balance sheet, compared with 94.5% five periods ago. This is the readily available cushion.
The accumulated result is -$780 million and remains below zero. The number alone does not explain whether losses, dividends or repurchases were the main cause.
Conclusion
G1 Therapeutics's balance sheet profile remains vulnerable. Lower liabilities and capital accumulation are the main routes to improvement.
Annual Balance Sheet G1 Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
19.1 M | -18.5 M | -145 M | -186 M | -259 M | -369 M | -104 M | -47.3 M | -22.9 M | - | - | - | - |
Long Term Debt |
50 M | 75 M | 75 M | 20 M | 9.54 M | - | - | - | - | - | - | - | - |
Long Term Debt Current |
1.28 M | 1.14 M | 1.12 M | 988 K | 682 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 9.54 M | 88 K | 79 K | - | - | - | - | - | - |
Total Current Liabilities |
29.7 M | 35.6 M | 27.6 M | 23.4 M | 19.8 M | 12.4 M | 11.7 M | 5.62 M | - | - | - | - | - |
Total Liabilities |
86.2 M | 119 M | 111 M | 51.2 M | 29.3 M | 12.4 M | 11.8 M | 5.62 M | 2.17 M | - | - | - | - |
Deferred Revenue |
620 K | 7 K | 31 K | 237 K | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-780 M | -732 M | -584 M | -436 M | -337 M | -214 M | -129 M | -65 M | -31.7 M | - | - | - | - |
Total Assets |
122 M | 188 M | 254 M | 229 M | 285 M | 371 M | 105 M | 48.2 M | 23.9 M | - | - | - | - |
Cash and Cash Equivalents |
32.2 M | 94.6 M | 221 M | 207 M | 269 M | 369 M | 104 M | 47.3 M | 22.9 M | - | - | - | - |
Book Value |
35.4 M | 68.7 M | 144 M | 177 M | 256 M | 359 M | 93.4 M | 42.6 M | 21.7 M | - | - | - | - |
Total Shareholders Equity |
35.4 M | 68.7 M | 144 M | 177 M | 256 M | 359 M | 93.4 M | -65 M | -31.7 M | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet G1 Therapeutics
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
32.9 M | 37.1 M | 51.6 M | 50 M | 50 M | 75 M | 5.62 M | 75 M | 75 M | 75 M | 6.75 M | 30 M | 30 M | 30 M | 20 M | 20 M | 20 M | 8.62 M | 9.54 M | 9.84 M | 1.09 M | 1.18 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
74.1 M | 74.3 M | 86.2 M | 90.1 M | 90.3 M | 117 M | 119 M | 121 M | 121 M | 118 M | 111 M | 65.2 M | 63.6 M | 63.1 M | 51.2 M | 60.8 M | 49.8 M | 27.1 M | 29.3 M | 31.1 M | 19 M | 12.7 M | 12.4 M | 13.8 M | 14.1 M | 12.6 M | 11.8 M | 11.8 M | 11.8 M | 11.8 M | 5.62 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
949 K | 396 K | 620 K | 686 K | 143 K | 505 K | 7 K | 9 K | 10 K | 17 K | 31 K | 26 K | 185 K | 154 K | 237 K | 14 M | 237 K | 237 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-796 M | -790 M | -780 M | -769 M | -751 M | -760 M | -732 M | -698 M | -673 M | -634 M | -584 M | -544 M | -502 M | -463 M | -436 M | -411 M | -399 M | -368 M | -337 M | -301 M | -269 M | -238 M | -214 M | -190 M | -170 M | -150 M | -129 M | -112 M | -96.5 M | -129 M | -65 M | -65 M | -65 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
98.7 M | 102 M | 122 M | 133 M | 148 M | 162 M | 188 M | 167 M | 187 M | 218 M | 254 M | 243 M | 277 M | 309 M | 229 M | 258 M | 254 M | 257 M | 285 M | 317 M | 332 M | 352 M | 371 M | 393 M | 191 M | 196 M | 105 M | 120 M | 134 M | 105 M | 48.2 M | 48.2 M | 48.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
15.1 M | 19.9 M | 32.2 M | 52.6 M | 55.9 M | 68.2 M | 94.6 M | 93.2 M | 144 M | 183 M | 221 M | 212 M | 244 M | 279 M | 207 M | 238 M | 234 M | 242 M | 269 M | 300 M | 325 M | 348 M | 369 M | 391 M | 188 M | 194 M | 104 M | 118 M | 133 M | 104 M | 47.3 M | 47.3 M | 47.3 M | - | 22.9 M | - | - | - | 3.69 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
24.6 M | 27.7 M | 35.4 M | 43 M | 57.5 M | 45 M | 68.7 M | 46 M | 66.3 M | 100 M | 144 M | 178 M | 213 M | 245 M | 177 M | 197 M | 204 M | 229 M | 256 M | 286 M | 313 M | 339 M | 359 M | 379 M | 177 M | 183 M | 93.4 M | 108 M | 122 M | 93.4 M | 42.6 M | 48.2 M | 48.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
24.6 M | 27.7 M | 35.4 M | 43 M | 57.5 M | 45 M | 68.7 M | 46 M | 66.3 M | 100 M | 144 M | 178 M | 213 M | 245 M | 177 M | 197 M | 204 M | 229 M | 256 M | 286 M | 313 M | 339 M | 359 M | 379 M | 177 M | 183 M | 93.4 M | 109 M | 124 M | 93.4 M | -65 M | -65 M | -65 M | - | -31.7 M | - | - | - | -10.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of G1 Therapeutics, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Britain
Israel
Germany
Canada
Russia
Schweiz
